Baird raised the firm’s price target on Medtronic to $84 from $77 and keeps a Neutral rating on the shares. The firm said they delivered its fourth consecutive quarter of MSD growth on another beat and raise, while also providing key pipeline updates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDT:
- Early notable gainers among liquid option names on November 21st
- Medtronic sees Q3 organic revenue growth 4%-4.5%
- Medtronic (NYSE:MDT) Gains on Healthy Q2 Performance
- Options Volatility and Implied Earnings Moves Today, November 21, 2023
- Medtronic raises FY24 EPS view to $5.13-$5.19 from $5.08-$5.16, consensus $5.12
